1. Home
  2. PSNL vs ESPR Comparison

PSNL vs ESPR Comparison

Compare PSNL & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$6.01

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSNL
ESPR
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
731.9M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
PSNL
ESPR
Price
$6.01
$3.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$12.20
$8.75
AVG Volume (30 Days)
1.9M
15.5M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
33.58
60.71
EPS
N/A
N/A
Revenue
$69,648,000.00
$403,135,000.00
Revenue This Year
$15.34
N/A
Revenue Next Year
$41.46
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$3.84
$0.73
52 Week High
$11.50
$4.18

Technical Indicators

Market Signals
Indicator
PSNL
ESPR
Relative Strength Index (RSI) 48.40 71.53
Support Level $5.81 $2.37
Resistance Level $6.99 $3.18
Average True Range (ATR) 0.45 0.10
MACD 0.07 0.17
Stochastic Oscillator 70.08 96.74

Price Performance

Historical Comparison
PSNL
ESPR

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: